Mitsune Tanimoto

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 707 citations · Full text

Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines

Fumihiko Hayakawa, Masayuki Towatari, Hitoshi Kiyoi et al. · Oncogene · 2000 · 559 citations

Signal Transduction, Signaling Pathway, Cell Regulation +9

The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers

Masaki Tokumo, Shinichi Toyooka, Katsuyuki Kiura et al. · Clinical Cancer Research · 2005 · 495 citations · Full text

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Michinori Ogura, Takashi Ishida, Kiyohiko Hatake et al. · Journal of Clinical Oncology · 2014 · 357 citations · Full text

All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group [see comments]

A Kanamaru, Y Takemoto, Mitsune Tanimoto et al. · Blood · 1995 · 250 citations